Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lantus Loss Drags Down Sanofi's Diabetes Franchise

This article was originally published in Scrip

Executive Summary

A nearly 20% drop in US sales of Sanofi's top-seller Lantus was largely to blame for a 6.6% fall in its diabetes franchise sales in the third quarter, leading the French pharma to lower its forecasts for its leading therapy segment.

You may also be interested in...



Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss

During third-quarter earnings report, Brandicourt said he remains confident about Sanofi's prospects in oncology despite losing the takeover fight for Medivation, although he didn't rule out another mid-sized bolt-on attempt if the opportunity arose.

Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected

Sanofi is putting more pressure on Medivation to accept its $9.3bn acquisition offer by proposing to replace the biotechnology company's and Xtandi developer's entire board of directors.

Waiting Game For Minerva After Roluperidone US Filing

The firm’s potential new therapy for the negative symptoms of schizophrenia is now in the hands of the US Food and Drug Administration – some have concerns over whether the supporting data will be enough.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC030189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel